Cue Biopharma (NASDAQ:CUE - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($4.42) EPS for the quarter, missing the consensus estimate of ($2.24) by ($2.18), Zacks reports. Cue Biopharma had a negative return on equity of 620.06% and a negative net margin of 435.83%.
Cue Biopharma Price Performance
Shares of NASDAQ:CUE traded down $2.02 during trading on Monday, reaching $14.10. 210,952 shares of the company were exchanged, compared to its average volume of 331,642. The business's fifty day simple moving average is $23.94 and its 200-day simple moving average is $107.17. Cue Biopharma has a 12-month low of $4.97 and a 12-month high of $45.50. The firm has a market capitalization of $102.37 million, a PE ratio of -0.52 and a beta of 2.79.
Insider Activity at Cue Biopharma
In other Cue Biopharma news, insider Sumita Ray sold 1,844 shares of the firm's stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.05, for a total transaction of $51,724.20. Following the transaction, the insider directly owned 116,701 shares in the company, valued at $3,273,463.05. This trade represents a 1.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Michael Vincent Meluzio sold 1,144 shares of Cue Biopharma stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.05, for a total value of $32,089.20. Following the sale, the vice president directly owned 47,817 shares of the company's stock, valued at approximately $1,341,266.85. This trade represents a 2.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 14,075 shares of company stock worth $389,260. Company insiders own 14.56% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on CUE. B. Riley Financial initiated coverage on shares of Cue Biopharma in a research note on Friday, September 18th. They issued a "buy" rating and a $83.00 price objective for the company. Zacks Research raised Cue Biopharma to a "hold" rating in a research note on Monday, September 21st. Weiss Ratings downgraded Cue Biopharma from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, August 27th. Finally, Wall Street Zen lowered Cue Biopharma from a "sell" rating to a "strong sell" rating in a research note on Saturday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $83.00.
Check Out Our Latest Stock Report on CUE
Cue Biopharma Company Profile
(
Get Free Report)
Cue Biopharma, Inc. is a biotechnology company developing biologic medicines designed to selectively engage and modulate T cells. Its Immuno-STAT platform is intended to direct immune activity toward disease-specific targets, with potential applications in cancer and autoimmune disorders. The company's research has included cancer candidates such as CUE-101, designed to target HPV16-positive cancers, and CUE-102, developed to target cancers expressing the WT1 protein. Cue Biopharma has also pursued programs intended to influence immune responses in autoimmune disease.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cue Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cue Biopharma wasn't on the list.
While Cue Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.